This study shows #SARSCoV2 upregulates #CD147, driving extended infection and immune imbalance; #Meplazumab blocks CD147–spike interaction, restores immune balance, and mitigates severe #COVID19, highlighting CD147 as a therapeutic target.

#OpenAccess #STTT: doi.org/10.1038/s413...

#SARSCoV2 triggers AHR‑mediated #CD147 up‑regulation, reduces ACE2, and drives immune imbalance through #M2macrophage signaling, while #Meplazumab disrupts CD147‑spike binding, restores immune balance, and mitigates severe #COVID19.

#OpenAccess in #STTT: doi.org/10.1038/s413...

📢 #LAQV Webinars
Join us Dec 10, 12h WET!
👉 Lucília Saraiva on beating #hard-to-treat cancer with a first-in-class DDR #inhibitor
👉 Sara Granja on #CD147 & #immunosurveillance
👉 Andreia M. B. da Costa on #pharmacotoxicology of #psychedelics
Chair: Conceição Santos
💻 meet.google.com/kes-ocwa-mfv

Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial - Signal Transduction and Targeted Therapy Signal Transduction and Targeted Therapy - Meplazumab, a CD147 antibody, for severe COVID-19: a double-blind, randomized, placebo-controlled, phase 3 clinical trial

This phase 3 trial shows that the #humanized #CD147 antibody #meplazumab significantly lowered 14, 28, and 56-day mortality, rapidly reduced #viralload, and improved multiple clinical outcomes in severe #COVID19 patients. #medsky

#STTT #OpenAccess: doi.org/10.1038/s413...

How does SARS-CoV-2 cause lymphopenia when T cells barely express ACE-2 receptors? Researchers reveal both direct and indirect mechanisms of SARS-CoV-2-induced lymphopenia, highlighting the role of CD147 and alternative viral entry routes into T cells.

How does SARS-CoV-2 cause lymphopenia when T cells barely express ACE-2 receptors? 🔬🦠📊 www.news-medical.net/news/2024070... #COVID19 #SARSCoV2 #TCells #Lymphopenia #Immunology #CD147 #CytokineStorm #ViralInfection #MedicalScience